Step-by-step guides, research summaries, and treatment overviews — reviewed by oncology navigators and written clearly for patients, families, and caregivers.
From newly diagnosed to relapsed and refractory — we publish what patients actually need to understand their options.
What are you looking for today?
CancerFax Insights exists because cancer patients face decisions that are genuinely hard — not because of lack of will, but because the information landscape is fragmented, fast-moving, and often written for clinicians, not families.
Every insight published here is reviewed by our oncology navigation team before it goes live. We focus on the questions patients actually ask us: What is this treatment? Who qualifies? What should I prepare? What should I ask my doctor?
Use the search and filters below to find what's most relevant to your situation.
Step-by-step patient guide
Before agreeing to CAR-T therapy, families need to understand eligibility criteria, the manufacturing timeline, expected side effects, and what happens if the therapy fails. This guide walks through every question your team should be able to answer.
Browse by the topic most relevant to where you are in your cancer journey right now.
Compare options, evaluate trade-offs, understand what questions to ask before agreeing to a specific protocol.
How trial matching works, eligibility logic explained, document checklists, and what to expect during screening.
NGS testing, biomarker-based treatment matching, liquid biopsy, tumour mutation burden, and targeted therapy guides.
Cross-border treatment pathways, China and India access, visa planning, cost estimates, and logistics walk-throughs.
Practical guides for families, partners, and adult children walking alongside someone in cancer treatment.
How to prepare records, frame clinical questions, compare opinions, and navigate specialist review across borders.
Search, filter, and explore all published insights — by cancer type, treatment category, clinical trial readiness, or stage of your journey.
Search across cancer types, treatments, mutations, drugs, and trials
Brain Cancer
MGMT promoter methylation predicts benefit from temozolomide chemotherapy, IDH mutation determines whether a tumour is true GBM or a lower-grade glioma, and H3K27M identifies diffuse midline gliomas — understanding these results is essential for every brain tumour patient.
Hormone Therapy
ER, PR, and HER2 status — determined by immunohistochemistry on the breast tumour biopsy — are the three most important biomarkers in breast cancer. They define which systemic treatments will work, determine prognosis, and determine treatment duration. Understanding what these results mean empowers patients to ask the right questions about their treatment plan.
Gastric Cancer
Trastuzumab deruxtecan (T-DXd, Enhertu, DS-8201a) is a HER2-directed antibody-drug conjugate that demonstrated a 51% objective response rate and significant overall survival benefit in second-line HER2-positive gastric cancer in the DESTINY-Gastric01 trial — establishing it as the standard second-line treatment for this biomarker-defined population.
Gastric Cancer
Zolbetuximab (IMAB362) is a first-in-class anti-CLDN18.2 monoclonal antibody that has demonstrated significant overall survival improvement in CLDN18.2-high, HER2-negative advanced gastric cancer in two Phase III trials (SPOTLIGHT and GLOW) — establishing it as a new first-line standard for this biomarker-defined patient population.
CancerFax Services
Precision oncology uses biomarker testing — including IHC, FISH, NGS, and liquid biopsy — to match cancer patients with treatments that target the specific molecular drivers of their tumour, rather than treating all cancers of the same organ type identically. Getting the right biomarker panel at the right time is now one of the most consequential decisions in cancer care.
Gastric Cancer
Gastric cancer targeted therapy has expanded rapidly from the single HER2 target of 2010 to a multi-biomarker landscape including HER2, CLDN18.2, FGFR2b, VEGFR2, and emerging targets — with trastuzumab, T-DXd, zolbetuximab, and ramucirumab as the established approved agents and a robust Chinese clinical trial pipeline extending the horizon further.
Neuro-Oncology
Temozolomide (TMZ) is an oral alkylating chemotherapy agent that forms the backbone of the Stupp protocol for glioblastoma — given concurrently with radiotherapy (75 mg/m²/day) and then as adjuvant monotherapy (150–200 mg/m², 5 of 28 days × 6 cycles). MGMT promoter methylation is the key predictive biomarker: methylated patients achieve median OS of 21–23 months vs 12–14 months for unmethylated patients with standard TMZ.
insight
Advanced cancer treatments may be relevant when the patient’s cancer type, stage, biomarker profile, previous treatment history, current disease status, and physical fitness match the requirements for an approved therapy, an off-label option, or a clinical trial. Eligibility often depends on pathology, IHC, NGS or molecular testing, imaging reports, organ function, blood counts, performance status, and specialist review. Some treatments are mainly used in selected cancers, while others remain investigational. CancerFax helps patients organize r
insight
When cancer progresses after treatment, the first step is to confirm what “progression” means in your case. Doctors usually review recent scans, symptoms, blood tests, tumor markers, pathology, prior treatments, and sometimes new biopsy or biomarker testing. Progression may lead to a change in treatment, local therapy for selected sites, supportive care, clinical trial screening, or a second opinion. Biomarker testing may help identify targeted therapy, immunotherapy, or trial options for some patients with advanced or recurrent cancer.[1] Canc
Where are you in your cancer journey? Find insights matched to your current situation.
Understand your diagnosis, staging, reports, and first-line options before making major decisions.
Read newly-diagnosed insightsExplore second opinions, molecular testing, clinical trials, and international advanced options.
Explore next-step insightsLearn how trial matching, eligibility review, and mutation-based screening actually work.
View clinical trial insightsUnderstand how destination, treatment availability, cost, and expertise shape cross-border decisions.
Compare destinationsCurated reading lists for patients going deep into a specific treatment category or clinical question.
Cell & gene therapy
Precision oncology
Advanced radiation & local therapies
Explore insights and guides organised by the treatment modality most relevant to your case.
Find content specific to your diagnosis — from treatment overviews to clinical trial access and second opinion guidance.
Clinical trial access
CancerFax connects patients with clinical trials in China, India, and leading global centres — including phase I and II trials closed to international enrolment through standard channels.
500+
active clinical trials across China, India, and leading global centres
40+
cancer types with current advanced therapy access pathways
12+
years of patient navigation experience in cross-border oncology
Insights our navigation team recommends most often to patients starting their research.
Treatment guide · 8 min
02Second opinion · 6 min
03Precision oncology · 10 min
04Clinical trials · 7 min
05Clinical trials · 9 min
06Precision oncology · 5 min
A note from the CancerFax team
CancerFax Insights is editorially independent of the hospitals, pharmaceutical companies, and treatment centres we work with. Our navigation team writes what patients need to hear — not what any institution wants them to read.
That means we tell patients when a treatment is likely out of reach, when a clinical trial has closed, and when the evidence for a new therapy is still thin. We believe informed patients make better decisions and have better outcomes — even when the honest answer is harder to hear.
— CancerFax oncology navigation team
How our content is produced, reviewed, and how to use it effectively.
Our oncology navigators review your medical records, explain your options in plain language, and help you access the right specialists, trials, and treatment centres — wherever you are in the world.
Every navigation request is reviewed by a qualified oncology professional. We do not recommend treatments without reviewing your medical records.
